ACUTE MYELOID LEUKAEMIA (AML)
Clinical trials for ACUTE MYELOID LEUKAEMIA (AML) explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKAEMIA (AML) trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKAEMIA (AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for AML patients: experimental drug IPN60340 enters key trial
Disease control Not yet recruitingThis study tests whether adding the experimental drug IPN60340 to standard medicines (azacitidine and venetoclax) helps more people with newly diagnosed acute myeloid leukemia (AML) achieve complete remission. About 450 adults who cannot have intensive chemotherapy will take part…
Matched conditions: ACUTE MYELOID LEUKAEMIA (AML)
Phase: PHASE2, PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug cocktail aims to wipe out lingering leukemia
Disease control Not yet recruitingThis study tests whether combining two oral drugs, sorafenib and venetoclax, can eliminate leftover leukemia cells in people with acute myeloid leukemia (AML) who still have measurable residual disease (MRD) after initial treatment. About 87 participants will receive the drugs fo…
Matched conditions: ACUTE MYELOID LEUKAEMIA (AML)
Phase: PHASE2, PHASE3 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New blood test could personalize AML treatment
Diagnosis Not yet recruitingThis study tests a new blood test (5hmC) to see if it can help doctors choose between two standard treatments for acute myeloid leukemia (AML): a milder drug (hypomethylating agent) or strong chemotherapy. About 112 newly diagnosed adults will have their blood tested after initia…
Matched conditions: ACUTE MYELOID LEUKAEMIA (AML)
Phase: PHASE2 • Sponsor: The Methodist Hospital Research Institute • Aim: Diagnosis
Last updated Jun 27, 2026 09:11 UTC